Premium
DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis
Author(s) -
Cai Xiaofeng,
Xing Junjie,
Long Courtney L,
Peng Qisheng,
Humphrey Mary Beth
Publication year - 2017
Publication title -
journal of bone and mineral research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.882
H-Index - 241
eISSN - 1523-4681
pISSN - 0884-0431
DOI - 10.1002/jbmr.3205
Subject(s) - rankl , osteoclast , syk , rank ligand , microbiology and biotechnology , chemistry , bone resorption , bone remodeling , bone marrow , signal transducing adaptor protein , signal transduction , receptor , activator (genetics) , macrophage colony stimulating factor , osteoprotegerin , medicine , endocrinology , biology , in vitro , macrophage , tyrosine kinase , biochemistry
Osteoclastogenesis is essential for bone remodeling and normal skeletal maintenance. Receptor activator of NF‐κB ligand (RANKL) promotes osteoclast differentiation and function but requires costimulation of immunoreceptor tyrosine‐based activation motif (ITAM)‐coupled immunoreceptors. Triggering receptor expressed on myeloid cells‐2 (TREM2) coupled to ITAM‐adaptor protein DNAX activation protein 12kDA (DAP12) provides costimulation of intracellular calcium signaling during osteoclastogenesis. Previously, we found that downstream of kinase‐3 (DOK3) physically associates with DAP12 to inhibit toll‐like receptor (TLR)‐induced inflammatory signaling in macrophages. However, whether and how DOK3 modulates DAP12‐dependent osteoclastogenesis is unknown and the focus of this study. Bone microarchitecture and histology of sex‐ and age‐matched wild‐type (WT) and DOK3‐deficient ( DOK3 ‐/‐ ) mice were evaluated. Male and female DOK3 ‐/‐ mice have significantly reduced trabecular bone mass compared with WT mice with increased TRAP+ osteoclasts in vivo. In vitro, DOK3 ‐/‐ bone marrow‐derived macrophages (BMMs) have increased macrophage colony‐stimulating factor (M‐CSF)‐induced proliferation and increased sensitivity to RANKL‐induced osteoclastogenesis. Compared with WT, DOK3 ‐/‐ osteoclasts are significantly larger with more nuclei and have increased resorptive capacity. Mechanistically, DOK3 limits osteoclastogenesis by inhibiting activation of Syk and ERK in response to RANKL and M‐CSF. DOK3 is phosphorylated in a DAP12‐dependent manner and associates with Grb2 and Cbl. Compared with DAP12 ‐/‐ mice with high bone mass, DOK3 ‐ and DAP12 ‐ doubly deficient mice (DKO) have normalized bone mass, indicating that DOK3 also limits DAP12‐independent osteoclastogenesis in vivo. In vitro osteoclasts derived from DKO mice are mononuclear with poor resorptive capacity similar to DAP12 ‐/‐ osteoclasts. Histomorphometry reveals that DOK3 ‐/‐ mice also have reduced osteoblast parameters. DOK3 ‐/‐ osteoblasts have reduced in vitro osteoblastogenesis and increased osteoprotegerin (OPG) to RANKL expression ratio compared with WT osteoblasts. Co‐culture of WT and DOK3 ‐/‐ osteoblasts with pre‐osteoclasts reveals a reduced capacity of DOK3 ‐/‐ osteoblasts to support osteoclastogenesis. These data indicate that DOK3 regulates bone remodeling by negatively regulating M‐CSF‐ and RANKL‐mediated osteoclastogenesis and positively regulating osteoblastogenesis. © 2017 American Society for Bone and Mineral Research.